The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Androgen receptor inhibitor–induced “BRCAness” and PARP inhibition are synthetically lethal for castration-resistant prostate cancer
Open accessAbstract
Androgen receptor inhibition induces a “BRCAness” state that may be exploited with PARP inhibitors in patients with advanced prostate cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R., Naishadham, D., & Jemal, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20138 · Cited by 10,679
Integrative Genomic Profiling of Human Prostate Cancer
Taylor, B. S., Schultz, N., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B. S., Arora, V. K., Kaushik, P., Cerami, E., Reva, B., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.026 · Cited by 3,701
Integrative Clinical Genomics of Advanced Prostate Cancer
Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.001 · Cited by 3,645
The mutational landscape of lethal castration-resistant prostate cancer
Grasso, C. S., Wu, Y.-M., Robinson, D. R., Cao, X., Dhanasekaran, S. M., Khan, A. P., Quist, M. J., Jing, X., Lonigro, R. J., Brenner, J. C., et al. (2012) · Nature · doi:10.1038/nature11125 · Cited by 2,517
DNA double-strand breaks: signaling, repair and the cancer connection
Khanna, K. K., & Jackson, S. P. (2001) · Nature Genetics · doi:10.1038/85798 · Cited by 2,455
THE TOXICITY OF POISONS APPLIED JOINTLY1
BLISS, C. I. (1939) · Annals of Applied Biology · doi:10.1111/j.1744-7348.1939.tb06990.x · Cited by 2,419
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
Mateo, J., Carreira, S., Sandhu, S., Miranda, S., Mossop, H., Perez-Lopez, R., Nava Rodrigues, D., Robinson, D., Omlin, A., Tunariu, N., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506859 · Cited by 2,185
The DNA damage response and cancer therapy
Lord, C. J., & Ashworth, A. (2012) · Nature · doi:10.1038/nature10760 · Cited by 1,649
Punctuated Evolution of Prostate Cancer Genomes
Baca, S. C., Prandi, D., Lawrence, M. S., Mosquera, J. M., Romanel, A., Drier, Y., Park, K., Kitabayashi, N., MacDonald, T. Y., Ghandi, M., et al. (2013) · Cell · doi:10.1016/j.cell.2013.03.021 · Cited by 1,320
Homologous Recombination and Human Health: The Roles of BRCA1, BRCA2, and Associated Proteins
Prakash, R., Zhang, Y., Feng, W., & Jasin, M. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a016600 · Cited by 869
Sandhu, S. K., Schelman, W. R., Wilding, G., Moreno, V., Baird, R. D., Miranda, S., Hylands, L., Riisnaes, R., Forster, M., Omlin, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70240-7 · Cited by 562
Self-citationAndrogen Receptor Signaling Regulates DNA Repair in Prostate Cancers
Polkinghorn, W. R., Parker, J. S., Lee, M. X., Kass, E. M., Spratt, D. E., Iaquinta, P. J., Arora, V. K., Yen, W.-F., Cai, L., Zheng, D., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0172 · Cited by 559
Loblaw, D. A., Virgo, K. S., Nam, R., Somerfield, M. R., Ben-Josef, E., Mendelson, D. S., Middleton, R., Sharp, S. A., Smith, T. J., Talcott, J., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.1949 · Cited by 555
Brenner, J. C., Ateeq, B., Li, Y., Yocum, A. K., Cao, Q., Asangani, I. A., Patel, S., Wang, X., Liang, H., Yu, J., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.010 · Cited by 415
A Hormone–DNA Repair Circuit Governs the Response to Genotoxic Insult
Goodwin, J. F., Schiewer, M. J., Dean, J. L., Schrecengost, R. S., de Leeuw, R., Han, S., Ma, T., Den, R. B., Dicker, A. P., Feng, F. Y., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0108 · Cited by 364
Poly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future Development
Scott, C. L., Swisher, E. M., & Kaufmann, S. H. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.8848 · Cited by 355
PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies
Lee, J.-M., Ledermann, J. A., & Kohn, E. C. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt384 · Cited by 352
Self-citationSlinker, B. K. (1998) · Journal of Molecular and Cellular Cardiology · doi:10.1006/jmcc.1998.0655 · Cited by 277
RAD51 paralogs: Roles in DNA damage signalling, recombinational repair and tumorigenesis
Suwaki, N., Klare, K., & Tarsounas, M. (2011) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2011.07.019 · Cited by 273
Bone metastasis in prostate cancer: emerging therapeutic strategies
Sturge, J., Caley, M. P., & Waxman, J. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.67 · Cited by 256
Trapping Poly(ADP-Ribose) Polymerase
Shen, Y., Aoyagi-Scharber, M., & Wang, B. (2015) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.222448 · Cited by 230
PARP inhibitors: A new era of targeted therapy
Tangutoori, S., Baldwin, P., & Sridhar, S. (2015) · Maturitas · doi:10.1016/j.maturitas.2015.01.015 · Cited by 152
DNA damage response and prostate cancer: defects, regulation and therapeutic implications
Karanika, S., Karantanos, T., Li, L., Corn, P. G., & Thompson, T. C. (2014) · Oncogene · doi:10.1038/onc.2014.238 · Cited by 111
Self-citationLiu, C., Srihari, S., Cao, K. L., Chenevix‐Trench, G., Simpson, P. T., Ragan, M. A., & Khanna, K. K. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku284 · Cited by 107
Pitroda, S. P., Pashtan, I. M., Logan, H. L., Budke, B., Darga, T. E., Weichselbaum, R. R., & Connell, P. P. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008291 · Cited by 99
Talarico, C., Dattilo, V., D’Antona, L., Menniti, M., Bianco, C., Ortuso, F., Alcaro, S., Schenone, S., Perrotti, N., & Amato, R. (2016) · Cellular Physiology and Biochemistry · doi:10.1159/000447885 · Cited by 92
Aparicio, A. M., Tzelepi, V., Araujo, J. C., Guo, C. C., Liang, S., Troncoso, P., Logothetis, C. J., Navone, N. M., & Maity, S. N. (2010) · The Prostate · doi:10.1002/pros.21301 · Cited by 87
Self-citationLi, L., Chang, W., Yang, G., Ren, C., Park, S., Karantanos, T., Karanika, S., Wang, J., Yin, J., Shah, P. K., et al. (2014) · Science Signaling · doi:10.1126/scisignal.2005070 · Cited by 84
Self-citationWillers, H., Gheorghiu, L., Liu, Q., Efstathiou, J. A., Wirth, L. J., Krause, M., & von Neubeck, C. (2015) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2015.05.007 · Cited by 75
PARP Inhibitors in Cancer Therapy: Promise, Progress, and Puzzles
Ellisen, L. W. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.01.047 · Cited by 60
Ratner, E., Sartorelli, A. C., & Lin, Z. P. (2012) · Current Opinion in Oncology · doi:10.1097/cco.0b013e3283564230 · Cited by 57
Liu, T., Gao, H., Yang, M., Zhao, T., Liu, Y., & Lou, G. (2014) · Tumor Biology · doi:10.1007/s13277-014-1770-y · Cited by 49
The convergence of DNA damage checkpoint pathways and androgen receptor signaling in prostate cancer
Ta, H. Q., & Gioeli, D. G. (2014) · Endocrine Related Cancer · doi:10.1530/erc-14-0217 · Cited by 43
Day, T. F., Mewani, R. R., Starr, J. M., Li, X., Chakravarty, D., Ressom, H. W., Zou, X., Eidelman, O., Pollard, H. B., Srivastava, M., et al. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-6539-7_7 · Cited by 41
Lowe, J. M., Nguyen, T., Grimm, S. A., Gabor, K. A., Peddada, S. D., Li, L., Anderson, C. W., Resnick, M. A., Menéndez, D., & Fessler, M. B. (2016) · Cell Death and Differentiation · doi:10.1038/cdd.2016.130 · Cited by 38
Self-citationCastro, E., Mateo, J., Olmos, D., & Bono, J. S. D. (2016) · The Cancer Journal · doi:10.1097/ppo.0000000000000219 · Cited by 29
Poly(ADP-ribose)polymerase (PARP) Inhibitors: From Bench to Bedside
Plummer, R. (2014) · Clinical Oncology · doi:10.1016/j.clon.2014.02.007 · Cited by 23
Targeted therapy in the treatment of castration-resistant prostate cancer.
Derleth, C. L., & Yu, E. Y. (2013) · PubMed · Cited by 20
The emerging role of serum/glucocorticoid-regulated kinases in cancer
Castel, P., & Scaltriti, M. (2016) · Cell Cycle · doi:10.1080/15384101.2016.1232071 · Cited by 8
Cited by
State-of-the-art strategies for targeting the DNA damage response in cancer
Pilié, P. G., Tang, C., Mills, G. B., & Yap, T. A. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0114-z · Cited by 1,189
Genetics and biology of prostate cancer
Wang, G., Zhao, D., Spring, D. J., & DePinho, R. A. (2018) · Genes & Development · doi:10.1101/gad.315739.118 · Cited by 750
PARP and PARG inhibitors in cancer treatment
Slade, D. (2020) · Genes & Development · doi:10.1101/gad.334516.119 · Cited by 667
Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology
Schaeffer, E. M., Srinivas, S., Adra, N., An, Y., Barocas, D., Bitting, R., Bryce, A., Chapin, B., Cheng, H. H., D’Amico, A. V., et al. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.0050 · Cited by 596
Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics
Ding, L., Bailey, M. H., Porta-Pardo, E., Thorsson, V., Colaprico, A., Bertrand, D., Gibbs, D. L., Weerasinghe, A., Huang, K.-L., Tokheim, C., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.033 · Cited by 399
Self-citation
Metadata
- Authors
- Li, L., Karanika, S., Yang, G., Wang, J., Park, S., Broom, B. M., Manyam, G. C., Wu, W., Luo, Y., Basourakos, S., Song, J. H., Gallick, G. E., Karantanos, T., Korentzelos, D., Azad, A. K., Kim, J., Corn, P. G., Aparicio, A. M., Logothetis, C. J., Troncoso, P., Heffernan, T., Toniatti, C., Lee, H.-S., Lee, J.-S., Zuo, X., Chang, W., Yin, J., & Thompson, T. C.
- Venue
- Science Signaling
- Published
- 2017-05-23
- Volume
- 10
- Issue
- 480
- ISSN
- 1937-9145 (ISSN-L)
- 1945-0877
- OpenAlex
- W2619512186
- Cited by
- 295
- References
- 39
- FWCI
- 8.62
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.